Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

pharmafile | November 7, 2018 | News story | Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes 

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint and “significantly reduced” the occurrence of major cardiovascular events (MACE) in patients with type 2 diabetes mellitus.

In the study, MACE included cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke.

The REWIND trial set itself apart from many similar studies by merit of its small population of participants with establish cardiovascular disease – just  31% – which allowed for a more insightful look into Trulicity’s effects on a broader range of those with type 2 diabetes.  

Additionally, the study had the longest median follow-up period of any CV outcomes  trial in the GLP-1 receptor agonist class, at more than five years.

“The REWIND study was ambitious, assessing whether dulaglutide could protect a broad range of people with type 2 diabetes, including a high proportion of patients without established cardiovascular disease, from experiencing a cardiovascular event,” explained Dr Arash Tahbaz, Senior Medical Director at Eli Lilly and Company UK and Northern Europe. “The initial study outcomes are compelling and we look forward to analysing and reporting all of the data.”

Matt Fellows

Related Content


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …


Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C …

Latest content